Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
antibodies, Biological, ALL, AML, apoptosis, Leukemia, Non-Biological, CLL, Diseases, drug-drug interaction, Lymphoma (any), CAR-Ts, Combinations, Therapies, Hodgkin Lymphoma, Mantle Cell Lymphoma, chemotherapy, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Biological Processes, DNA damage, Technology and Procedures, immunotherapy, Lymphoid Malignancies, Clinically relevant, Myeloid Malignancies, pharmacology, Quality Improvement , TKI, integrative -omics, molecular testing, metabolomics, molecular interactions, pathways, proteomics, signal transduction
Type: Oral
Hematology Disease Topics & Pathways:
antibodies, Biological, ALL, AML, apoptosis, Leukemia, Non-Biological, CLL, Diseases, drug-drug interaction, Lymphoma (any), CAR-Ts, Combinations, Therapies, Hodgkin Lymphoma, Mantle Cell Lymphoma, chemotherapy, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Biological Processes, DNA damage, Technology and Procedures, immunotherapy, Lymphoid Malignancies, Clinically relevant, Myeloid Malignancies, pharmacology, Quality Improvement , TKI, integrative -omics, molecular testing, metabolomics, molecular interactions, pathways, proteomics, signal transduction
Monday, December 7, 2020: 7:00 AM-8:30 AM
Moderators:
Scott F. Huntington, MD, MPH, Yale University School of Medicine
and
Nicolas Nassar, PhD, Cincinnati Children Hospital Medical Center
Disclosures:
Huntington: AbbVie: Consultancy; Astrazeneca: Honoraria; Bayer: Consultancy, Honoraria; Celgene: Consultancy, Research Funding; DTRM: Research Funding; Genentech: Consultancy; Novartis: Consultancy; Pharmacyclics: Honoraria; TG Therapeutics: Research Funding; Flatiron Health: Consultancy; BeiGene: Consultancy.
7:00 AM
7:15 AM
7:30 AM
7:45 AM
8:00 AM
8:15 AM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH